Insulin-Like Growth Factor Binding Protein-3 Interacts with Autocrine Motility Factor/Phosphoglucose Isomerase (AMF/PGI) and Inhibits the AMF/PGI Function

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2516-2522

  Mishra, Suresh ^a   Raz, Avrahram ^b   Murphy, Liam J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; AUTOCRINE MOTILITY FACTOR; GLUCOSE 6 PHOSPHATE ISOMERASE; SOMATOMEDIN BINDING PROTEIN 3; STREPTAVIDIN;

APOPTOSIS; ARTICLE; BIOTINYLATION; BREAST CANCER; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN MCF 7; COMPLEX FORMATION; CONTROLLED STUDY; CROSS LINKING; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; AUTOCRINE MOTILITY FACTOR; BREAST NEOPLASMS; CATALYSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; PHOSPHORYLATION; PROTEIN BINDING;

EID: 1942442191     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2877     Document Type: Article

References (32)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
2. DeMellow JSM, Baxter RC. Growth hormone dependent insulin like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human fibroblasts. Biochem Biophys Res Commun 1988;156:199-204.
3. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mole Endocrinol 1996;9:361-7.
4. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 1995;6:205-12.
5. Lalou C. Lassarre C, Binoux MA. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996;137:3206-12.
6. Hong J, Zhang G, Dong F, Rechler MM. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 2002;277:10489-97.
7. Zadeh SM, Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 1997;138:3069-72.
8. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993;268:26045-8.
9. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999;140:1319-28.
10. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993;268:14964-71.
11. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997;272:20572-6.
12. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996;56:2960-3.
13. Shimizu K, Tani M, Watanabe H, et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999;456:295-300.
14. Mishra S, Murphy LJ. Phosphorylation of insulin-like growth factor (IGF) binding protein-3 by breast cancer cell membranes enhances IGF-I binding. Endocrinology 2003;144:4042-50.
15. Talukder AH, Adam L, Raz A, Kumar R. Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res 2000;60:474-8.
16. Gracy RW, Tilley BE. Phosphoglucose isomerase of human erythrocytes and cardiac tissue Methods Enzymol 1975;41:392-400.
17. Niinaka Y, Paku S, Haga A, Watanabe H, Raz A. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 1998;58:2667-74.
18. Haga A, Niinaka Y, Raz A. Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochim Biophys Acta 2000;1480:235-44.
19. Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 2003;63:242-9.
20. Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986;83:3302-6.
21. Chaput M, Claes V, Portetelle D, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature (Lond.) 1988;332:454-5.
22. Gurney ME, Apatoff BR, Spear GT, et al. Neuroleukin, a lymphokine product of lectin-stimulated T cells. Science (Wash. DC) 1986;234:574-81.
23. Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW. The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 1996;87:4502-6.
24. Funasaka T, Haga A, Raz A, Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 2001;284:116-25.
25. Silletti S, Raz A. Autocrine motility factor is a growth factor. Biochem Biophys Res Commun 1993;194:447-57.
26. Janosi JB, Ramsland PA, Mott MR, Firth SM, Baxter RC, Delhanty PJ. The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes. Structural determination by molecular modeling and electron microscopy. J Biol Chem 1999;274:23328-32.
27. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-1-induced insulin-like growth factor-1 receptor signaling in Ishikawa endometrial cancer cells. J Biol Chem 1997;272:16514-20.
28. Delli-Bovi P, Curatola AM, Newman KM, et al. Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol Cell Biol 1988;8:2933-41.
29. Rubartelli A, Cozzolino F, Talio M, Sitia RA. novel secretory pathway for interleukin-1β, a protein lacking a signal sequence. EMBO J 1990;9:1503-10.
30. Silletti S, Rax A. Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Curr Top Microbiol Immunol 1996;213:137-69.
31. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok, E.,. The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney and breast cancer. Cancer Investig 1990;8:351-6.
32. McCaig C, Fowler CA, Laurence NJ, et al. Differential interactions between IGFBP-3 and transforming growth factor-β (TGF-β) in normal vs cancerous breast epithelial cells. Br J Cancer 2002;86:1963-9.